Dental Management of Medication-Related OSTEONECROSIS of the JAW: WHILE RARE, THIS PATHOLOGY HAS DEVASTATING EFFECTS ON PATIENT HEALTH AND QUALITY OF LIFE
- PMID: 38187891
- PMCID: PMC10767836
Dental Management of Medication-Related OSTEONECROSIS of the JAW: WHILE RARE, THIS PATHOLOGY HAS DEVASTATING EFFECTS ON PATIENT HEALTH AND QUALITY OF LIFE
Conflict of interest statement
The authors have no commercial conflicts of interest to disclose
Figures
References
-
- Mark AM. What Is MRONJ? J Am Dent Assoc 2021;152:710. - PubMed
-
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–1117. - PubMed
-
- Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons’ Position Paper on medication-related osteonecrosis of the jaw–2022 update Available at: aaoms.org/docs/govt_affairs/advocacy_white_papers/mronj_position_paper.pdf. Accessed August 8, 2023. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous